Total Septolete spray mest.prim. 30ml vial dosed 250doz 1 pc

$8.69

Total Septolete spray mest.prim. 30ml vial dosed 250doz 1 pc

5 in stock

Quantity:

Description

Composition
Active substance:
1 dose spray contains:
Benzydamine hydrochloride 0.150 mg
Cetylpyridinium chloride monohydrate 0.526 mg, equivalent to 0.500 mg of cetylpyridinium chloride
1 dose – about 0.1 ml of solution. 30 ml of the product in primary packaging contain 250 doses.
Excipients:
Ethanol 26.760 mg glycerol 10.450 mg macrogol glitserilgidroksistearat 0.250 mg, 0.092 mg sodium saccharin, peppermint leaf oil 0.100 mg purified water to 0.1 ml.
Description:
The clear solution from colorless to yellowish.
Product form:
Spray for topical dosage, 0.15 mg + 0.5 mg / dose. 30 ml (250 doses) of the drug in the vial, high density polyethylene, provided with a metering device (pump) to the spray head with the applicator tube of composite material, and a colored protective cap of polypropylene. 1 vial together with instructions for use placed into cardboard pack.
Contraindications
Hypersensitivity to the active ingredients or to any auxiliary ingredients.
Children up to age 12 years.
Carefully
Increased sensitivity to aspirin or other nonsteroidal anti-inflammatory drugs, bronchial asthma (r. H. In history), liver disease, alcoholism, craniocerebral injury, brain diseases, pregnancy, breast-feeding.
Dosage
0.15 mg + 0.5 mg / dose
Indications
Symptomatic therapy of oral pain and inflammatory diseases of upper respiratory tract (different etiology).
Interaction with other drugs
It has not been studied. simultaneous application should be avoided with other drugs from the group of antiseptics.
Overdose
Symptoms toxic manifestations benzydamine overdose include: agitation, convulsions, sweating, ataxia, vomiting and chills. Signs and symptoms of intoxication by ingestion of significant quantities of cetylpyridinium chloride: nausea, vomiting, edema, cyanosis, asphyxiation followed by paralysis of the respiratory muscles, central nervous system depression, hypotension, and coma. The lethal dose for humans is about 1-3 g Treatment: due to the absence of a specific antidote, treatment of acute intoxication benzydamine symptomatic. Treatment of overdoses cetylpyridinium chloride also symptomatic. In case of overdose, seek medical attention.
pharmachologic effect
Pharmacological group:
Nonsteroidal anti-inflammatory drug + antiseptic.
Pharmacodynamics:
Benzydamine – a non-steroidal anti-inflammatory agent, anti-inflammatory, analgesic and local anesthetic action. Cetylpyridinium chloride – preservative from the group consisting of quaternary ammonium compounds having antimicrobial, antifungal, virucidal action.
Pharmacokinetics:
Suction
Of the two active substances – cetyl pyridinium chloride and benzydamine – mucosally absorbed only benzydamine. Therefore, cetylpyridinium chloride does not come into engagement with benzydamine pharmacokinetic at the system level.
Benzydamine absorption through the mucous membranes of the oral cavity and pharynx has been shown, by identifying active substance in the serum, the amount of which, however, it was not sufficient to provide systemic action.
In the application of benzydamine in the dosage form of a spray for topical use in the recommended doses suction slightly.
Distribution
The volume of distribution of all forms of the same drug.
breeding
Withdrawal takes place in the kidneys to a greater extent in the form of inactive metabolites. The half-life and total body clearance is similar for all dosage forms.
Pregnancy and breast-feeding
Use of the drug Septolete® total is during pregnancy and breastfeeding period is possible only after consultation with your doctor, if the intended benefits to the mother outweighs the potential risk to the fetus and child.
Conditions of supply of pharmacies
Without a prescription.
side effects
Classification of the incidence of side effects, recommended by the World Health Organization (WHO): very common> 1/10, often by> 1/100 to 1/1000 to 1/10000 to
Disorders of immune system: rare: hypersensitivity reactions.
Disorders of the nervous system: unknown frequency numbness of the oral mucosa.
Violations of the respiratory system, thorax and mediastinum: rare: bronchospasm.
Disorders of the gastrointestinal tract: Very rare: irritation of the oral mucosa, burning sensation in the mouth.
Violations of the skin and subcutaneous tissue disorders: Rare: rash, photosensitivity. frequency is unknown: angioedema, pruritus.
If any of these instructions side effects are compounded, or if you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
Carefully read the manual before you start using the product. Keep these instructions, it may be needed again. If you have any questions, consult your doctor.
Medicines that you are being treated, meant to you personally, and should not be transferred to other persons as it may harm them even if you have the same symptoms that you have.
In applying the drug Septolete® total it is possible to develop hypersensitivity reactions to the drug. In this case, it is recommended to discontinue treatment and consult a doctor for the appointment of appropriate therapy.
If there is ulceration of the mucous membrane of the oropharynx, the patient should seek medical advice if symptoms persist for more than three days.
Use of the drug Septolete® total is not recommended in patients with hypersensitivity to aspirin or other nonsteroidal antiinflammatory drugs.
Preparation Septolete® total is not to be used in conjunction with anionic compounds (e.g., present in toothpaste). Therefore, it is not recommended to use the drug immediately before or after brushing.
Avoid contact of the product Septolete® total over with mucous membranes of the eyes.
The spray should not be inhaled.
Preparation Septolete® total is contains a small amount of ethanol 96%: 26.760 mg / 1 dose spray.
After opening the bottle of the drug should be used within 6 months.
The effect on the ability to operate vehicles, machinery
Total Septolete® drug has no effect on the ability to drive vehicles and operate machinery.
Storage conditions
At temperatures above 25 C, in the original package.
Keep out of the reach of children.
Dosing and Administration
Locally.
Adults
For a single dose you should press the spray head 2 times.
It is recommended to apply every 2 hours, 5 times a day for 4 days.
Do not exceed this dose.
To achieve an optimum effect is not recommended to apply the preparation Septolete® total is immediately before or after brushing.
If after treatment there is no improvement or there are new symptoms, you should consult with your doctor.
Use drug only according to the application and in those doses which are specified in the instruction.
If necessary, please consult your physician before using the drug.
You should see your doctor if your symptoms worsen or do not improve after 4 days of treatment.
Mode of application:
Before the first use of the drug should Septolete® total over several times to press the spray head of the metering device to obtain a uniform dispersion. If the drug Septolete® total is not used for a long time (for at least 1 week), press on the spray head of the metering device 1 time to obtain a uniform dispersion. -Before using, remove the color cap. -Wide open your mouth, please send an applicator tube in your mouth, hold your breath and press the spray head 2 times. -After each use of the drug Septolete® Total cover spray head colored protective cap.
When pressed on the spray head released 0.1 ml of a solution as a spray which contains 0.15 mg of benzydamine and 0.5 mg of cetylpyridinium chloride.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Krka UTS

There are no reviews yet.

Add your review